Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.63, $0.09 better than the analyst estimate of $2.54. Revenue for the quarter came in at $989.2 million versus the consensus estimate of $974.65 million.

GUIDANCE:

Charles River Laboratories sees FY2022 EPS of $10.80-$10.95, versus the consensus of $10.80.

• Revenue growth, reported 10.0% – 11.0%

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.